Shares of health-care companies declined as traders retreated from riskier niches of the market, such as technology and biotechology. Coherus BioSciences fell after the Food and Drug Administration requested further work on its application for a "biosimilar" generic version of Amgen's Neulasta drug for a blood-borne side effect of cancer.
Continue Reading Below
-Rob Curran, firstname.lastname@example.org
(END) Dow Jones Newswires
June 12, 2017 16:27 ET (20:27 GMT)